OXFORD, England--(BUSINESS WIRE)--Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced the launch of its research use variaTECT™ genetic ...

Cytox Ltd, (Cytox) a leading developer of assays for risk assessment and prediction of dementia, announced the start of two landmark exploratory clinical trials designed to evaluate a new blood ...

Affymetrix and Cytox have agreed to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer’s disease (AD) and mild ...

Cytox Limited Richard Pither, CEO, +44 (0)1865 338018 [email protected] www.cytoxgroup.com Affymetrix Media Contact Mindy Lee-Olsen VP, Marketing Services +1 408 731 5523 Mindy_lee ...

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimer’s disease ...

The U.K.’s Cytox has launched the research use of its variaTECT genetic biomarker test for assessing the risk of Alzheimer’s disease. ... (assessed via a diagnostic assay) ...

U.K. diagnostics developer Cytox raised nearly $2.5 million in new funding to help expand work on the development of a viable Alzheimer's biomarker. CEO Richard Pither said in a statement that the ...

Affymetrix Inc. AFFX recently announced that it has entered into a strategic partnership with Cytox, a developer of assays for risk assessment and prediction of dementia. Under the terms of the ...

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, and Affymetrix (Nasdaq:AFFX), a leading provider of translational research and diagnostic solutions ...